Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,294 | -63,308 | -45,968 | -28,264 | -13,265 |
| Depreciation Amortization | -1,013 | -990 | -215 | 135 | 101 |
| Other Working Capital | -553 | 1,992 | 2,055 | 786 | -1,037 |
| Other Operating Activity | 3,436 | 10,989 | 7,902 | 5,016 | 2,374 |
| Operating Cash Flow | $-17,424 | $-51,317 | $-36,226 | $-22,327 | $-11,827 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 19,820 | -220,108 | -219,340 | -156,261 | 490 |
| PPE Investments | -87 | -879 | -591 | -281 | -76 |
| Investing Cash Flow | $19,733 | $-220,987 | $-219,931 | $-156,542 | $414 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 662 | 532 | 381 | 156 |
| Other Financing Activity | 0 | -427 | -427 | -427 | 0 |
| Financing Cash Flow | $N/A | $235 | $105 | $-46 | $156 |
| Beginning Cash Position | 26,500 | 298,569 | 298,569 | 298,569 | 298,569 |
| End Cash Position | 28,809 | 26,500 | 42,517 | 119,654 | 287,312 |
| Net Cash Flow | $2,309 | $-272,069 | $-256,052 | $-178,915 | $-11,257 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,424 | -51,317 | -36,226 | -22,327 | -11,827 |
| Capital Expenditure | -87 | -918 | -630 | -320 | -76 |
| Free Cash Flow | -17,511 | -52,235 | -36,856 | -22,647 | -11,903 |